Parkinsonism after taking ecstasy.

作者信息

Mintzer S, Hickenbottom S, Gilman S

出版信息

N Engl J Med. 1999 May 6;340(18):1443. doi: 10.1056/nejm199905063401817.

DOI:10.1056/nejm199905063401817

PMID:10328712

Abstract

摘要

相似文献

Parkinsonism after taking ecstasy.

N Engl J Med. 1999 May 6;340(18):1443. doi: 10.1056/nejm199905063401817.

More about parkinsonism after taking ecstasy.

N Engl J Med. 1999 Oct 28;341(18):1400-1.

More about parkinsonism after taking ecstasy.

N Engl J Med. 1999 Oct 28;341(18):1400; author reply 1401. doi: 10.1056/NEJM199910283411815.

More about parkinsonism after taking ecstasy.

N Engl J Med. 1999 Oct 28;341(18):1400; author reply 1401.

What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?

Mov Disord. 2003 Nov;18(11):1219-23. doi: 10.1002/mds.10643.

The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).

Psychopharmacology (Berl). 2004 Jan;171(2):231-3. doi: 10.1007/s00213-003-1600-1. Epub 2003 Nov 21.

Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.

Psychopharmacology (Berl). 2003 Jun;167(4):449-50. doi: 10.1007/s00213-003-1447-5. Epub 2003 Apr 8.

Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Psychopharmacology (Berl). 2004 Jan;171(2):229-30. doi: 10.1007/s00213-003-1599-3. Epub 2003 Nov 21.

MDMA and Parkinsonism.

N Engl J Med. 2003 Jul 3;349(1):96-7. doi: 10.1056/NEJMc030208.

Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.

Mov Disord. 2003 Nov;18(11):1378-81. doi: 10.1002/mds.10623.

引用本文的文献

Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.

J Med Case Rep. 2023 Sep 23;17(1):405. doi: 10.1186/s13256-023-04147-x.

Psychostimulants and movement disorders.

Front Neurol. 2015 Apr 20;6:75. doi: 10.3389/fneur.2015.00075. eCollection 2015.

Monoamine reuptake inhibitors in Parkinson's disease.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25.

Substance of abuse and movement disorders: complex interactions and comorbidities.

Curr Drug Abuse Rev. 2012 Sep;5(3):243-53. doi: 10.2174/1874473711205030243.

Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study.

Neuropsychopharmacology. 2011 Mar;36(4):735-43. doi: 10.1038/npp.2010.201. Epub 2010 Dec 15.

The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.

Int J Methods Psychiatr Res. 2005;14(4):167-85. doi: 10.1002/mpr.6.

Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Psychopharmacology (Berl). 2004 May;173(3-4):249-63. doi: 10.1007/s00213-004-1788-8. Epub 2004 Apr 9.

Psychopharmacology (Berl). 2004 Jan;171(2):229-30. doi: 10.1007/s00213-003-1599-3. Epub 2003 Nov 21.

The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.

CMAJ. 2001 Oct 2;165(7):917-28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验